<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04868292</url>
  </required_header>
  <id_info>
    <org_study_id>SPR206-102</org_study_id>
    <secondary_id>CDMRP-JW180095-A</secondary_id>
    <secondary_id>2020-006019-52</secondary_id>
    <nct_id>NCT04868292</nct_id>
  </id_info>
  <brief_title>Study to Assess the Intrapulmonary Pharmacokinetics of SPR206 in Healthy Volunteers</brief_title>
  <official_title>A Phase 1, Single-Center, Open-Label Study to Assess the Intrapulmonary Pharmacokinetics of SPR206 by Comparing the Plasma, Epithelial Lining Fluid, and Alveolar Macrophage Concentrations Following the Intravenous Administration of SPR206 in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Spero Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>United States Department of Defense</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
  </sponsors>
  <source>Spero Therapeutics</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the intrapulmonary pharmacokinetics (PK), including epithelial lining fluid (ELF)&#xD;
      and alveolar macrophage (AM) concentrations, of SPR206 as well as plasma concentrations of&#xD;
      SPR206 in healthy adult volunteers.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 3, 2021</start_date>
  <completion_date type="Actual">September 29, 2021</completion_date>
  <primary_completion_date type="Actual">September 16, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area under the concentration-time curve from time 0 to 8 hours (AUC0-8) for ELF, AM, and plasma</measure>
    <time_frame>8 hours after the start of the third study drug IV infusion</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum observed concentration (Cmax) for ELF, AM, and plasma</measure>
    <time_frame>8 hours after the start of the third study drug IV infusion</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Minimum concentration (Cmin) for ELF, AM, and plasma</measure>
    <time_frame>8 hours after the start of the third study drug IV infusion</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to the maximum observed concentration (Tmax) for ELF, AM, and plasma</measure>
    <time_frame>8 hours after the start of the third study drug IV infusion</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of Treatment-Emergent Adverse Events</measure>
    <time_frame>Day -1 to Day 7</time_frame>
    <description>To assess the incidents of treatment-emergent adverse events following three 100mg SPR206 intravenous doses administered every 8 hours. AEs will be classified by System Organ Class (SOC) and Preferred Term (PT). Incidence, frequency, severity and duration will be presented.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of abnormal vital sign assessments - blood pressure</measure>
    <time_frame>Day -1 to Day 7</time_frame>
    <description>To assess the incidents of abnormal systolic and diastolic blood pressure assessments following three 100mg SPR206 intravenous doses administered every 8 hours. Frequency count of significant changes from baseline will be presented.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of abnormal vital sign assessments - body temperature</measure>
    <time_frame>Day -1 to Day 7</time_frame>
    <description>To assess the incidents of abnormal body temperature assessments following three 100mg SPR206 intravenous doses administered every 8 hours. Frequency count of significant changes from baseline will be presented.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of abnormal vital sign assessments - heart rate</measure>
    <time_frame>Day -1 to Day 7</time_frame>
    <description>To assess the incidents of abnormal heart rate assessments following three 100mg SPR206 intravenous doses administered every 8 hours. Frequency count of significant changes from baseline will be presented.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of abnormal vital sign assessments - respiratory rate</measure>
    <time_frame>Day -1 to Day 7</time_frame>
    <description>To assess the incidents of abnormal respiratory rate assessments following three 100mg SPR206 intravenous doses administered every 8 hours. Frequency count of significant changes from baseline will be presented.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of abnormal physical exam assessments</measure>
    <time_frame>Day -1 to Day 7</time_frame>
    <description>To assess the incidents of abnormal body system assessments following three 100mg SPR206 intravenous doses administered every 8 hours. Changes from baseline in physical examination findings will be classified as Normal, Abnormal NCS, and Abnormal CS. Frequency counts will be presented.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of abnormal ECG assessments - heart rate</measure>
    <time_frame>Day -1 to Day 7</time_frame>
    <description>To assess the incidents of abnormal heart rate assessment following three 100mg SPR206 intravenous doses administered every 8 hours. Cardiac (12-Lead ECG) for heart rate will be classified as normal, abnormality that is NCS, and CS abnormality. Frequency counts by dose group and timepoint of collection will be presented.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of abnormal ECG assessments - PR, RR, QRS, QT and QTcF interval</measure>
    <time_frame>Day -1 to Day 7</time_frame>
    <description>To assess the incidents of abnormal PR interval, RR interval, QRS interval, QT interval and QTcF interval assessments following three 100mg SPR206 intravenous doses administered every 8 hours. Cardiac (12-Lead ECG) results will be classified as normal, abnormality that is NCS, and CS abnormality. Frequency counts by dose group and timepoint of collection will be presented.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of abnormal safety laboratory assessments</measure>
    <time_frame>Day -1 to Day 7</time_frame>
    <description>To assess the incidents of abnormal hematology, serum chemistry, coagulation and urinalysis assessments following three 100mg SPR206 intravenous doses administered every 8 hours. Frequency counts of significant changes from baseline will be presented.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">34</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>SPR206</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Healthy subjects meeting eligibility criteria will receive a total of three 100 mg SPR206 intravenous doses administered every 8 hours.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SPR206</intervention_name>
    <description>Three 100 mg SPR206 intravenous doses administered every 8 hours</description>
    <arm_group_label>SPR206</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Non-smoker for at least 12 months prior to screening for the study&#xD;
&#xD;
          -  BMI ≥ 18.5 and ≤ 32 (kg/m2) and weight between 55.0 and 100.0 kg (both inclusive)&#xD;
&#xD;
          -  Medically healthy without clinically significant abnormalities as assessed by the&#xD;
             Investigator based on screening medical history, physical examination, vital signs,&#xD;
             12-lead ECG, hematology, biochemistry, coagulation, and urinalysis&#xD;
&#xD;
          -  Forced expiratory volume in 1 second (FEV1) of at least 80% of predicted value at&#xD;
             screening&#xD;
&#xD;
          -  Ability and willingness to abstain from alcohol, caffeine, xanthine-containing&#xD;
             beverages or food from 48 hours prior to study drug administration until discharge&#xD;
             from the clinical unit&#xD;
&#xD;
          -  If male, must agree to use a condom and have a non-pregnant female partner of&#xD;
             childbearing potential agree to use a highly effective method of contraception&#xD;
&#xD;
          -  If female, must be of non-childbearing potential or, if female of childbearing&#xD;
             potential, a willingness to abstain from sexual activity or agree to use a high&#xD;
             effective method of contraception that could lead to pregnancy&#xD;
&#xD;
          -  Other inclusion criteria per protocol&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History or presence of significant oncologic, cardiovascular, pulmonary, hepatic,&#xD;
             renal, hematological, gastrointestinal, endocrine, immunologic, dermatologic, vascular&#xD;
             or neurological disease, including any acute illness or surgery within the past 3&#xD;
             months determined by the Investigator to be clinically relevant&#xD;
&#xD;
          -  Recent history (within 6 months) of known or suspected Clostridium difficile infection&#xD;
&#xD;
          -  History of seizure disorders&#xD;
&#xD;
          -  Positive urine drug, alcohol or cotinine testing at screening or check-in (Day -1)&#xD;
&#xD;
          -  Positive testing for human immunodeficiency virus (HIV), hepatitis B surface antigen&#xD;
             (HBsAg) or hepatitis C antibodies (HCV Ab)&#xD;
&#xD;
          -  Positive testing for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) at&#xD;
             screening or prior to first dosing&#xD;
&#xD;
          -  Presence of the following symptoms at screening or within 28 days prior to screening&#xD;
             or check-in (Day -1):&#xD;
&#xD;
               1. Fever, chills or sweats (temperature of 38 °C / 100.4 °F or higher)&#xD;
&#xD;
               2. Difficulty breathing&#xD;
&#xD;
               3. Cough&#xD;
&#xD;
               4. Sore throat&#xD;
&#xD;
               5. New or recent loss of taste or smell&#xD;
&#xD;
               6. Nausea, vomiting or diarrhea&#xD;
&#xD;
          -  Close contact with anyone who tested positive for SARS-CoV-2 infection within 28 days&#xD;
             prior to screening or check-in (Day -1)&#xD;
&#xD;
          -  Electrocardiogram (ECG) with QTcF interval duration equal or greater than 450 msec for&#xD;
             males and 470 msec for females&#xD;
&#xD;
          -  Subjects who have any of the following abnormalities on laboratory values at screening&#xD;
             or Check-In including:&#xD;
&#xD;
               1. White blood cell count &lt; 3,000/mm3, hemoglobin &lt; 11g/dL&#xD;
&#xD;
               2. Absolute neutrophil count ≤ 2,000/mm3, platelet count &lt;120,000/mm3&#xD;
&#xD;
               3. alanine aminotransferase (ALT) OR aspartate aminotransferase (AST) greater than&#xD;
                  the upper limit of normal (ULN) for the reference laboratory&#xD;
&#xD;
          -  History of substance abuse or alcohol abuse&#xD;
&#xD;
          -  Use of prescription medicine &amp; tobacco/nicotine or marijuana-containing products&#xD;
&#xD;
          -  A female who is pregnant or breastfeeding&#xD;
&#xD;
          -  Other exclusion criteria per protocol&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Melnick, MD</last_name>
    <role>Study Director</role>
    <affiliation>Spero Therapeutics Inc</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Medical Facility</name>
      <address>
        <city>Manchester</city>
        <zip>M23 9QZ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>April 13, 2021</study_first_submitted>
  <study_first_submitted_qc>April 27, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 30, 2021</study_first_posted>
  <last_update_submitted>November 16, 2021</last_update_submitted>
  <last_update_submitted_qc>November 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>pharmacokinetics</keyword>
  <keyword>alveolar macrophages (AM)</keyword>
  <keyword>epithelial lining fluid (ELF)</keyword>
  <keyword>intrapulmonary</keyword>
  <keyword>bronchoalveolar lavage</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

